Actos Victims File Minnesota Lawsuit
The latest lawsuit filed against the manufacturer of Actos, a type II diabetes drug that is allegedly dangerously defective, comes from a Minnesota couple.
William Blumenstine and Kathy Jo Williams filed their product liability lawsuit against Actos manufacturer Takeda on May 14, 2012 in United States’ District Court for the District of Minnesota. The lawsuit states that Mr. Blumenstine began taking the medication in 2004 to improve blood sugar that was high due to type II diabetes. He continued his use of Actos in 2008, but discontinued use shortly after experiencing hematuria and urinary retention. After having a cystoscopy performed, it was found that he had bladder cancer as identified by a tumor in his bladder. He had to undergo treatment and surgery to deal with his bladder cancer that is believed to have been caused by Actos.
There are many plaintiffs involved in lawsuits surrounding Actos and Takeda with claims that Takeda did not issue the proper warnings about the serious side effects. One of the side effects not warned about includes bladder cancer.
Actos was one of the 10 best selling medications in the U.S. in 2008. Worldwide sales total in the billions of dollars. While the drug is very effective in treating diabetes, it has been established that patients that use it for more than 12 months have an increased risk of developing bladder cancer. Germany and France have suspended the sale of Actos, but Takeda continues to sell the medication in the U.S.
Actos’s popularity is due to its ability to improve blood sugar control in patients with type II diabetes. Due to the condition affecting millions of individuals in the U.S., Actos is the most popular medication manufactured by Takeda. Thus far, a number of patients have been affected by the serious side effects and have taken legal action. If you have suffered serious side effects after taking the drug, contact a Minneapolis personal injury lawyer from TSR Injury Law - you may be eligible to file a damages lawsuit.
Free consultation. Ph: (612) TSR-TIME.